MAN

Equity

Veradermics ·Balance Sheet Statement·9 metrics

Breakdown

Loading...

Metrics

Additional paid-in capital

Accumulated other comprehensive income (loss)

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Stockholders' Equity Note, Subscriptions Receivable

Temporary Equity, Shares Subscribed but Unissued, Subscriptions Receivable

Retained earnings

Total liabilities and stockholders' equity

Total stockholders' equity